+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Olink Proteomics AB (OLK) - Product Pipeline Analysis, 2021 Update

  • PDF Icon

    Company Profile

  • 33 Pages
  • December 2021
  • GlobalData
  • ID: 5519792
Olink Proteomics AB (Olink) is a biotechnology company that offers products and services for human protein biomarker research. The company provides portfolio of products such as biomarkers, cardiovascular diseases panels, neurological disease panels, inflammation panels and oncology panels. Olink through its Proximity Extension Assay (PEA) technology develops multiplex immunoassay panels for human protein biomarker research. It works in collaboration with other organizations to develop new projects. The company through Olink Bioscience focuses on the development and commercialization of enabling molecular tools for life science research and molecular diagnostics. It also provides protein biomarker discovery data analysis services in Watertown and Sweden. The company also has operational presence in the US. Olink is headquartered in Uppsala, Sweden.

This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope:


  • The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
  • The report analyzes all pipeline products in development for the company Olink Proteomics AB
  • The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
  • The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
  • The report provides detailed description of products in development, technical specification and functions
  • The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.

Reasons to Buy:


  • Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
  • Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
  • To formulate effective Research & Development strategies
  • Develop market-entry and market expansion strategies
  • Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
  • Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio

Note: Some sections may be missing if data is unavailable for the company

Table of Contents

  • Olink Proteomics AB Company Overview
  • Olink Proteomics AB Company Snapshot
  • Olink Proteomics AB Pipeline Products and Ongoing Clinical Trials Overview
  • Olink Proteomics AB - Pipeline Analysis Overview
  • Olink Proteomics AB - Key Facts
  • Olink Proteomics AB - Major Products and Services
  • Olink Proteomics AB Pipeline Products by Development Stage
  • Olink Proteomics AB Pipeline Products Overview
  • Blood Test - Diagnostic Purposes
  • Blood Test - Diagnostic Purposes Product Overview
  • Blood Test - Ovarian Cancer
  • Blood Test - Ovarian Cancer Product Overview
  • cJun-Smad 2/3 Kit
  • cJun-Smad 2/3 Kit Product Overview
  • Companion Diagnostic Assay - Aromatase
  • Companion Diagnostic Assay - Aromatase Product Overview
  • Companion Diagnostic Assay - Trastuzumab
  • Companion Diagnostic Assay - Trastuzumab Product Overview
  • HER2-pEGFR Kit
  • HER2-pEGFR Kit Product Overview
  • s100A4 Kit
  • s100A4 Kit Product Overview
  • U-Rhythm Device
  • U-Rhythm Device Product Overview
  • Olink Proteomics AB - Key Competitors
  • Olink Proteomics AB - Key Employees
  • Olink Proteomics AB - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Recent Developments
  • Olink Proteomics AB, Recent Developments
Nov 11, 2021: Psomagen is partnering with Olink Proteomics, enabling unprecedented multi-omics clinical studies
Jun 23, 2021: Olink announces the new Explore 3072 high throughput proteomics platform, offering uncompromised data quality with coverage of all major biological pathways
May 20, 2021: Olink reports first quarter 2021 financial results and issues full year 2021 guidance
Apr 29, 2021: Olink to Report First Quarter 2021 Financial Results on May 20, 2021
Jun 21, 2019: Breakthrough biomarker blood test for ovarian cancer on the horizon
Aug 30, 2018: Olink Proteomics announces a new biomarker panel that expands its protein library to over 1000 high-quality assays
Dec 14, 2017: Olink Proteomics announces the availability of the most comprehensive, high-multiplex protein biomarker panel for mouse studies
Feb 16, 2017: Olink Proteomics announces the availability of three new biomarker panels focused on key biological processes with broad clinical relevance
Nov 29, 2016: Olink Proteomics announces the availability of three new biomarker panels to further explore the complexities of the human proteome
Sep 21, 2016: Olink Proteomics announces the availability of the broadest and most complete protein biomarker panel for immuno-oncology
Appendix
  • Methodology
  • About The Publisher
  • Contact The Publisher
  • Disclaimer

List of Tables
  • Olink Proteomics AB Pipeline Products and Ongoing Clinical Trials Overview
  • Olink Proteomics AB Pipeline Products by Equipment Type
  • Olink Proteomics AB Pipeline Products by Indication
  • Olink Proteomics AB, Key Facts
  • Olink Proteomics AB, Major Products and Services
  • Olink Proteomics AB Number of Pipeline Products by Development Stage
  • Olink Proteomics AB Pipeline Products Summary by Development Stage
  • Blood Test - Diagnostic Purposes - Product Status
  • Blood Test - Diagnostic Purposes - Product Description
  • Blood Test - Ovarian Cancer - Product Status
  • Blood Test - Ovarian Cancer - Product Description
  • cJun-Smad 2/3 Kit - Product Status
  • cJun-Smad 2/3 Kit - Product Description
  • Companion Diagnostic Assay - Aromatase - Product Status
  • Companion Diagnostic Assay - Aromatase - Product Description
  • Companion Diagnostic Assay - Trastuzumab - Product Status
  • Companion Diagnostic Assay - Trastuzumab - Product Description
  • HER2-pEGFR Kit - Product Status
  • HER2-pEGFR Kit - Product Description
  • s100A4 Kit - Product Status
  • s100A4 Kit - Product Description
  • U-Rhythm Device - Product Status
  • U-Rhythm Device - Product Description
  • Olink Proteomics AB, Key Employees
  • Olink Proteomics AB, Other Locations
  • Olink Proteomics AB, Subsidiaries
  • Glossary

List of Figures
  • Olink Proteomics AB Pipeline Products by Equipment Type
  • Olink Proteomics AB Pipeline Products by Development Stage

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • WntResearch AB
  • Cellectricon AB
  • Athera Biotechnologies AB